Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-marketing, Double-blind, Randomized Controlled Trial. (CSPPT)

NCT00794885 Phase 4 COMPLETED

The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.

Details

Lead sponsor	Shenzhen Ausa Pharmed Co.,Ltd
Phase	Phase 4
Status	COMPLETED
Enrolment	20702
Start date	2008-05
Completion	2014-06

Conditions

• Primary Hypertension

Interventions

• Enalapril/folic acid
• Enalapril maleate

Primary outcomes

• First attack of symptomatic stroke ( ischemic or hemorrhagic) — during the trial period
  Patients are followed-up every 3 months. All endpoint outcomes are assessed by the Endpoint Adjudication Committee of the study.

Countries

China